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MaeIII Restriction Fragment Length Polymorphism in exon 3 of the alcohol dehydrogenase II was assessed in serum from 467
randomly selected German women and 278 women with invasive breast cancer to evaluate the interaction between a
polymorphism of the alcohol dehydrogenase II gene, alcohol consumption and risk for breast cancer. In both groups, usual
consumption of different alcoholic beverages was asked for using semiquantitative food frequency questionnaires. We used
multivariable logistic regression to separately estimate the association between alcohol consumption and alcohol
dehydrogenase II polymorphism in the population sample and women with breast cancer. The alcohol dehydrogenase II
polymorphism was detected in 14 women from the population sample (3.0%) and in 27 women with invasive breast cancer
(9.7%). Frequency of alcohol consumption was independent of the genotype in the population sample. In women with breast
cancer, there was a signiﬁcant inverse association between the alcohol dehydrogenase II polymorphism and frequency of
alcohol consumption (adjusted case-only odds ratio over increasing frequency of alcohol consumption=0.5; P for
interaction=0.02). We observed a gene-environment interaction between the alcohol dehydrogenase II polymorphism,
alcohol consumption, and risk for breast cancer. Breast cancer risk associated with alcohol consumption may vary according to
the alcohol dehydrogenase II polymorphism, probably due to differences in alcohol metabolism.
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Alcohol might very well be one of the few modiﬁable risk factors
for breast cancer (Longnecker, 1994; Smith-Warner et al, 1998;
Singletary and Gapstur, 2001; Willett, 2001). Despite growing inter-
est in genetic polymorphisms of the enzymes involved in alcohol
metabolism for several diseases associated with alcohol comsump-
tion (Hines et al, 2001; McCarver, 2001; Yamauchi et al, 2001a,b),
data regarding the role of these polymorphisms as to the risk for
breast cancer are sparse (Freudenheim et al, 1999; Hines et al,
2000). These polymorphisms are good candidates for gene-environ-
ment interactions (Millikan et al, 1995), however, because they are
likely to inﬂuence the most plausible biologic mechanism linking
alcohol consumption to risk for breast cancer, i.e. endogenous
oestrogens.
In humans, alcohol is almost entirely metabolised by oxidative
detoxiﬁcation, mainly dependent on two enzymes, class I alcohol
dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH).
Both enzymes exhibit genetic polymorphisms inﬂuencing the rate
of conversion from alcohol to acetaldehyde and to acetate (Smith,
1986). The class I ADH isoenzymes are formed by dimeric associa-
tions of a, b, and g subunits controlled by three separate gene loci
ADH1, ADH2, and ADH3, respectively (Agarwal and Goedde,
1990). Despite recent reports regarding the ADH3 polymorphism
and risk for breast cancer (Freudenheim et al, 1999; Hines et al,
2000), nothing is known about the role of the less frequent but
metabolically more relevant ADH2 polymorphism and its interac-
tion with alcohol consumption for the risk of breast cancer.
The aim of the study was to test the a priori hypothesis of an
interaction between the ADH2-2 polymorphism alone, alcohol
consumption, and the risk for breast cancer in Caucasian women.
MATERIALS AND METHODS
We used the case-only design (Khoury and Flanders, 1996) to eval-
uate the interaction between the ADH2-2 polymorphism and
alcohol consumption with respect to the risk for breast cancer.
The case-only design has more power to assess gene-risk factor
interactions than the case-control design, but its applicability
depends on the independence of the genetic factor and the risk
factor in the population. Therefore, the independence between
the ADH2 polymorphism and frequency of alcohol consumption
was ﬁrst assessed in a random sample of the German population.
Random population sample
The population sample consisted of women selected from a
national health and nutrition survey conducted among healthy
people in the western part of Germany in 1987/1988. The survey
methodology has been previously described in detail (Schneider
et al, 1992; Speitling et al, 1992). In brief, a stratiﬁed probability
sample was drawn from the noninstitutionalised adult population
(518 years of age) of German nationality. With an overall partici-
pation rate of about 70%, 1132 women were recruited in the study.
Personal interviews were conducted at the participants’ homes and Received 10 May 2002; revised 12 June 2002; accepted 14 June 2002
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including alcohol consumption, and various life-style characteris-
tics. Blood samples were obtained by venipuncture after fasting
overnight from 965 women (85%). Sera were stored in the gas
phase of liquid nitrogen at 71308C.
Women with breast cancer
Women with breast cancer were recruited in the context of a state-
wide study on risk factors and diagnostic procedures for various
forms of cancer, including breast cancer, conducted in Saarland,
a state with about one million inhabitants in Western Germany.
The study was approved by local and regional institutional review
boards. Patients 80 years of age or younger, with a ﬁrst diagnosis of
invasive breast cancer between 1 October 1996 and 28 February
1998 were eligible and recruited for the study by their treating
physicians during the ﬁrst hospitalisation due to the cancer, typi-
cally several days to weeks after initial treatment (Arndt et al,
2002). Out of 458 patients deemed suitable for participation by
their treating physicians, 387 (85%) fulﬁlled all of the inclusion
criteria stated above and were willing to participate. After written
informed consent, interviews following a standardised question-
naire and blood drawings were performed by trained medical
doctors. The interview included detailed information on known
risk factors for breast cancer, including alcohol consumption
during the year preceding the onset of symptoms. Clinical and
pathological characteristics of the breast cancers, including meno-
pausal status, were abstracted from hospital records, including
pathology reports. Blood samples were obtained from 288 women
with breast cancer (74.4%, the remaining women did not consent
to blood drawing or blood drawing was not possible) and were
immediately transported to the study centre and centrifuged on
the same day. Sera were stored at 7808C. For the present analysis,
eight women with non-German nationality and two in whom
genotyping failed were excluded.
Genotyping
Serum samples from the population sample and women with
breast cancer were analysed separately and without further infor-
mation regarding the women (including their alcohol
consumption) according to the same protocol in a central labora-
tory at the Department of Obstetrics and Gynecology of the
University of Ulm. The analysis of MaeIII RFLP was based on
the PCR ampliﬁcation of a fragment using the following primers:
sense primer, 5'-AAT CTT TTC TGA ATC TGA ACA G-3', and
anti-sense primer 5'-GAA GGG GGG TCA CCA GGT TG-3'. All
PCRs were carried out in 25 ml aliquots containing 5 ml of denatu-
rated serum, 5 pmol of each primer, 1X reaction buffer, 50 mM
dNTPs, and 0.25 U Taq polymerase. The ampliﬁcation was for
30 cycles each consisting of 1 min denaturing at 948C, 1 min of
annealing at 608C and 1 min of extension at 728C. An initial dena-
turation step of 3 min at 948C and a ﬁnal extension at 728C for
5 min were used. PCR products were digested to completion with
MaeIII at 558C for 12 h. Digests were separated on a 12% polya-
crylamide gel. All ethidium bromide-stained fragments were
analysed on a UV source using an image analysis system. The
ADH2-2 allele of the polymorphism was deﬁned as the presence
of the MaeIII digestive site, according to a previous publication
(Goedde et al, 1992).
Alcohol consumption
In both the population sample and women with breast cancer,
consumption of different alcoholic beverages was assessed using a
semiquantitative food–frequency questionnaire. Women from the
population sample were asked about the usual number of days
per week on which they consumed different beverages as well as
the usual quantity of these beverages consumed per week (Mu ¨ller
et al, 2001). Women with breast cancer were asked about the usual
consumption of deﬁned quantities of different alcoholic beverages
(beer, wine, spirits) per day, week, or month in the year preceeding
the onset of symptoms. In all women, the usual frequency of
consumption of alcoholic beverages was categorised into less than
once a week, once a week, and more than once a week according
to the alcoholic beverage most often consumed.
Statistical analysis
Out of the random population sample, we randomly selected up to
two women within the same 5-year age-category for every woman
with breast cancer. We then described sociodemographic factors
and known or suspected risk factors for breast cancer in this
age-matched population sample and women with breast cancer.
The odds ratios (OR) and their 95% conﬁdence intervals (CI)
for the association between categories of alcohol consumption
and the ADH2 polymorphism were estimated separately in the
population sample and women with breast cancer using multivari-
able logistic regression. All analyses were controlled for age
(continuous), body mass index (weight in kg
2 height in m, contin-
uous), smoking (never, ever), age at menarche (continuous), parity
(0, 1, 2, 3 or more), and history of breast cancer in the mother.
The case-only analyses were additionally controlled for menopausal
status, age at menopause (continuous), and cumulative years of
hormone replacement therapy (continuous) (Colditz and Rosner,
2000).
RESULTS
The mean age of the population sample of 467 women was 54.9
years, slightly lower than the mean age of the 278 cases with inva-
sive breast cancer (57.2 years, see Table 1). The majority of women
with breast cancer (72.7%) were postmenopausal at the time of
diagnosis. Whereas the body mass index was slightly lower in the
population sample than in women with breast cancer, the preva-
lence of cigarette smoking (current and former) was virtually
identical (41.5%). In the population sample, the mean age at
menarche was 13.8 years compared to 13.5 years in women with
breast cancer. About one-third of all women had given birth to
two, and another third to three or more children. A family history
of breast cancer in the mother was reported by 18 women from the
population sample (3.9%) and 24 women with breast cancer
(8.6%).
The majority of women with breast cancer were postmenopausal
(72.7%) and had T1 (43.8%) or T2 (45.2%) tumours. Most cancers
were ductal (74.1%) and oestrogen (70.1%) as well as progesteron
Table 1 Description of random sample of German women and women
with invasive breast cancer
Population sample Breast cancer
N 467 278
Age (years), mean (s.d.) 54.9 (10.9) 57.2 (11.5)
BMI (kg m
72), mean (s.d.) 26.0 (4.5) 26.5 (4.9)
Cigarette smoking (ever), N (%) 194 (41.5) 114 (41.5)
Age at menarche (years), mean (s.d.) 13.8 (1.7) 13.5 (1.7)
Parity, N (%)
No child 79 (17.0) 41 (14.9)
1 child 85 (18.2) 60 (21.7)
2 children 147 (31.6) 84 (30.4)
3 or more children 155 (33.3) 91 (33.0)
Family history of breast cancer 18 (3.9) 24 (8.6)
(mother only), N (%)
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lymph nodes at the time of diagnosis (data not shown).
In the population sample, 14 heterozygotes of ADH2 (b1b2)
were detected (3.0%) compared to 27 heterozygotes in women with
breast cancer (9.7%, see Table 2). None of the women was b2b2
homozygote.
The proportion of women consuming alcoholic beverages less
often than once a week or more often than once a week was
approximately equal (around 40% each) in women from the popu-
lation sample (see Table 2). The prevalence of the ADH2
polymorphism by category of alcohol consumption ranged from
2.1–3.3% and was independent of the frequency of alcohol
consumption (adjusted OR for trend with increasing frequency
of alcohol consumption=0.9, P=0.9).
Since the frequency of alcohol consumption was independent of
the ADH2 polymorphism in the population sample, the possible
interaction between the ADH2 polymorphism and frequency of
alcohol consumption as to the risk for breast cancer could be
assessed using the case-only design. During the last year preceeding
the onset of symptoms, 117 women with breast cancer consumed
alcoholic beverages less often than once a week and 98 women
reported consumption of alcoholic beverages more often than once
a week. The prevalence of the ADH2 polymorphism monotonically
decreased with increasing frequency of alcohol consumption from
15.4% in women consuming alcoholic beverages less often than
once a week to 4.1% in women consuming alcoholic beverages
more often than once a week. The case-only analysis conﬁrmed
the inverse interaction between the ADH2 polymorphism and
frequency of alcohol consumption with respect to risk for breast
cancer. The adjusted case-only OR for once a week consumption
of alcoholic beverages compared to women consuming alcoholic
beverages less often was 0.5 (95% CI: 0.2–1.7). In women consum-
ing alcoholic beverages more often than once a week, this OR was
even more pronounced (OR=0.3; 95% CI: 0.1–0.9). There was a
statistically signiﬁcant trend for a lower prevalence of the ADH2
polymorphism with increasing frequency of alcohol consumption
(P=0.02).
Additional case-only analyses revealed that the observed interac-
tion was independent of menopausal status and any of the known
risk factors for breast cancer presented in Table 1, essentially
unchanged using usual amount (g day
71) of alcohol consumed
instead of frequency of consumption, and even more pronounced
(OR over increasing frequency of alcohol consumption=0.4; 95%
CI: 0.2–0.9) in women with oestrogen receptor positive tumours
(data not shown).
DISCUSSION
In a population based case-only study of women with breast cancer
we observed a previously unknown interaction between frequency
of alcohol consumption, the ADH2 polymorphism, and risk for
breast cancer.
The use of the case-only study design is dependent on the
assumption that the frequency of alcohol consumption does not
vary according to the genotype in the population. Since we, like
others (Gilder et al, 1993; Whitﬁeld et al, 1998; Borras et al,
2000), observed no association between ADH2 polymorphism
and alcohol consumption in women without breast cancer, we
could assess the interaction between these factors and risk for
breast cancer using the case-only analysis, which is more powerful
to detect gene-environment interactions than a case–control study
(Piegorsch et al, 1994). In contrast to a case–control analysis, our
analytic strategy has also the advantage of assessing associations
independently in women with identical data collection procedures
(i.e. ﬁrst within women from the population sample and then
within women with breast cancer) and therefore avoiding problems
of differential misclassiﬁcation often encountered in case-control
studies. Furthermore, the case-only design allowed to control for
menopausal status, age at menopause, and cumulative years of
hormone replacement therapy in the multivariable analysis as
recently suggested (Colditz and Rosner, 2000).
ADH2 is known as a key enzyme in the ﬁrst step of detoxiﬁca-
tion of alcohol to acetaldehyde. The ADH2-2 allele, which encodes
the more active b2-subunit, is more prevalent in Asian populations
(60–80%) than Caucasians (0–10%) (Goedde et al, 1992) and
leads to an increased metabolic rate in vitro (9.2 min
71 for b1b1
and 400 min
71 for b2b2 isoenzymes) (Bosron and Li, 1986).
Furthermore, the ADH2 polymorphism has been shown to increase
the alcohol elimination rate after alcohol consumption (Thomas-
son et al, 1993) and to inﬂuence the metabolism of alcohol in
peripheral tissues (Takeshita et al, 1996).
Blood alcohol levels have been associated with oestradiol levels,
which play a major role in the development of breast cancer (The
Endogenous Hormones and Breast Cancer Collaborative Group,
Table 2 ADH2 polymorphism according to frequency of alcohol consumption in the population sample and in women with invasive breast cancer
b1/b1 b1/b2 OR (95% CI)
a
N (%) N (%) Crude Adjusted
b
Population sample 453 (97.0) 14 (3.0)
Usual frequency of alcohol consumption
c
Less than once a week 174 (96.7) 6 (3.3) 1.0 reference 1.0 reference
Once a week 92 (97.9) 2 (2.1) 0.6 (0.1–3.2) 0.7 (0.1–3.5)
More than once a week 187 (96.9) 6 (3.1) 0.9 (0.3–2.9) 0.9 (0.3–2.9)
Crude Adjusted
e
Women with invasive breast cancers
d 251 (90.3) 27 (9.7)
Usual frequency of alcohol consumption
Less than once a week 99 (84.6) 18 (15.4) 1.0 reference 1.0 reference
Once a week 58 (92.1) 5 (7.9) 0.5 (0.2–1.3) 0.5 (0.2–1.7)
More than once a week 94 (95.9) 4 (4.1) 0.2 (0.1–0.7) 0.3 (0.1–0.9)
aOdds ratio and 95% conﬁdence interval from logistic regression; analysis in women with invasive breast cancer corresponds to case-only analysis of interaction between ADH2
polymorphism and frequency of alcohol consumption with respect to risk for breast cancer;
bFor age, body mass index (weight in kg/squared height in m), frequency of alcohol
consumption, smoking, age at menarche, and parity;
cOdds ratio for trend with increasing category of frequency of alcohol consumption (adjusted model)=0.9 (95% CI: 0.5–1.7);
Ptrend=0.9;
dOdds ratio for trend with increasing category of frequency of alcohol consumption (adjusted model)=0.5 (95% CI: 0.3–0.9); Ptrend=0.02;
eCase-only odds ratio
adjusted for age, body mass index (weight in kg/squared height in m), frequency of alcohol consumption, smoking, age at menarche, parity, menopausal status, age at menopause,
years of hormone replacement therapy, and history of breast cancer in the mother.
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blood alcohol levels and oestradiol levels in pre- (Reichman et al,
1993) and postmenopausal (Ginsburg et al, 1996, Ginsburg,
1999) women is not completely understood, the increased alcohol
elimination rate in individuals with the polymorphism may lead to
lower oestradiol levels and might therefore be an explanation for
the observed inverse interaction. Faster clearance of alcohol might
furthermore mitigate the depression of androgens and sex
hormone binding globulin associated with alcohol intake (Madigan
et al, 1998; Hines et al, 2000), the latter again leading to a
decreased bioavailability of oestrogens.
The difference in prevalence of the ADH2 polymorphism in the
population sample and in women with breast cancer is intruiging.
Is the ADH2 polymorphism a previously unknown risk factor for
breast cancer? This difference needs to be interpreted with caution.
Women from the population sample were recruited nationwide
and approximately 10 years before the recruitment of women with
breast cancer. The population sample has been found to be repre-
sentative of the German population (Schneider et al, 1992),
however. We furthermore found no regional differences in the
prevalence of the ADH2 polymorphism in the population sample
(P=0.4, data not shown) and changes in the prevalence of the poly-
morphism over such a short time period are unrealistic. Population
stratiﬁcation or confounding by different genotypes, which are
culturally linked to alcohol consumption, is unlikely to introduce
relevant bias in this exclusively German population with very simi-
lar genetic background (Wacholder et al, 2000). Finally, although
the polymorphism was analysed separately in both groups, the
same methods were used in the same laboratory by the same tech-
nicians.
ADH has been found in different organs not directly involved in
alcohol metabolism, including the breast (Saleem et al, 1984). In
combination with xanthine oxidoreductase, ADH may lead to the
formation of reactive oxygen species that themselves have been
linked to types of DNA damage typically observed in breast cancer
and therefore contribute to breast carcinogenesis (Wright et al,
1999). Furthermore, Class I ADH plays an important role in the
provitamin A (beta-carotene) metabolism, oxidizing all-trans-reti-
nol and 9-cis-retinol, and might play a role in hydroxysteroid
metabolism (Duester, 2000). Therefore, there seems to be evidence
that some forms of ADH may play important roles in human
tissues other than the liver, including the breast.
Although we carefully controlled for potential confounding
factors in our analysis, the potential for residual confounding by
additional factors cannot entirely be ruled out. In particular, the
observed risk and interaction may not be entirely due to the
ADH2 polymorphism itself, but also to the linkage of ADH2 with
other genes that are associated with an increased risk for breast
cancer. ADH2 has been observed to be linked to ADH3 (Borras
et al, 2000) and the ADH3*1 genotype was observed to be a risk
factor for breast cancer in premenopausal women (Freudenheim
et al, 1999). However, given the stronger metabolic effects of
ADH2, the ADH3–breast cancer association might also be
confounded by ADH2.
In summary, we observed a previously unknown interaction
between alcohol consumption and the ADH2 polymorphism with
respect to risk for breast cancer. If replicated, the observed gene-
environment interaction might be a good example for the future
need of a concept for tailor-made preventive recommendations
taking individual genetic susceptibilities into account. It might,
however, also be a good example for the complexity and difﬁculties
in applying such recommendations in practice due to the low
prevalence of the ADH2 polymorphism in the caucasian popula-
tion.
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